Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.

Abstract:

BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in Chinese patients with curatively resected NSCLC. METHODS:A total of 1466 consecutive NSCLC patients who received curative surgery from January 1, 2005 to December 31, 2009 with complete data from pretreatment blood tests were enrolled in this retrospective study. Correlations between each blood test parameter and overall survival were examined by Kaplan-Meier method or Cox proportional hazards regression, followed by a stratification analysis of significant variables. RESULTS:Optimal cut-off values of 0.55 for neutrophil/white blood cell ratio (NWR), 0.28 for lymphocyte/white blood cell ratio (LWR), 0.09 for monocyte/white blood cell ratio (MWR), 2.06 for NLR, 0.35 for MLR, 204.00 for PLR, and 38.25 for platelet/white blood cell ratio (PWR) were identified using X-tile software. Univariate analysis suggested that NWR ≥ 0.55, LWR < 0.28, MWR ≥ 0.09, NLR ≥ 2.06, MLR ≥ 0.35, and PLR ≥ 204.00 predicted a poor prognosis in NSCLC patients. However, only NWR and MLR were identified as independent significant prognostic factors in multivariable analysis, especially in tumor node metastasis stage I and I/II/III NSCLCs. CONCLUSION:Pretreatment NWR, MWR, LWR, NLR, MLR, and PLR values are associated with poor overall survival for patients with curatively resected NSCLC. NWR and MLR are independent prognostic factors in curatively resected NSCLC.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Yuan C,Li N,Mao X,Liu Z,Ou W,Wang SY

doi

10.1111/1759-7714.12454

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

350-358

issue

4

eissn

1759-7706

issn

1759-7714

journal_volume

8

pub_type

杂志文章
  • Invasive thymoma with intravascular growth into the great veins and right atrium: A case report.

    abstract::Here, we present a case of invasive thymoma with intraluminal growth into the left and right brachiocephalic veins, superior vena cava and the right atrium. Resection of the mass, double partial upper lobe lobectomy and superior vena cava, and left and right brachiocephalic vein replacement were performed. Pathologica...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13242

    authors: Shen W,Cao Y,Wang X,Zhang P,Zhou Q

    更新日期:2020-05-01 00:00:00

  • Flap endonuclease-1 rs174538 G>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population.

    abstract:BACKGROUND:Esophageal cancer has a high mortality rate, particularly in Asia, and there are obvious racial differences in regard to incidence. The purpose of our study was to assess the genetic susceptibility of functional single nucleotide polymorphisms in flap endonuclease-1 (FEN1) in esophageal squamous cell carcino...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12422

    authors: Sang Y,Bo L,Gu H,Yang W,Chen Y

    更新日期:2017-05-01 00:00:00

  • Lung adenocarcinoma with anomalous bronchi and pulmonary veins preoperatively identified by computed tomography.

    abstract::A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12362

    authors: Tajima K,Uchida N,Sasamoto H,Okada T,Kohri T,Mogi A,Kuwano H

    更新日期:2016-09-01 00:00:00

  • Upregulation of phosphoserine phosphatase contributes to tumor progression and predicts poor prognosis in non-small cell lung cancer patients.

    abstract:BACKGROUND:Growing evidence indicates that high phosphoserine phosphatase (PSPH) expression is associated with tumor prognosis in many types of cancers. However, the role of PSPH in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to investigate the clinical significance of PSPH in NSCLC. M...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13064

    authors: Liao L,Yu H,Ge M,Zhan Q,Huang R,Ji X,Liang X,Zhou X

    更新日期:2019-05-01 00:00:00

  • Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.

    abstract::After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12416

    authors: Mengoli MC,Orsi G,Lococo F,Grizzi G,Barbieri F,Bertolini F,Rossi G,Novello S

    更新日期:2017-07-01 00:00:00

  • Validated LC-MS/MS method of Sphingosine 1-phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer.

    abstract:BACKGROUND:Sphingosine 1-phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore to develop a fast, a...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13409

    authors: Tang X,Chen H,Chen G,Duan C,Fan Q,Li H,Wang Y,Li Z,Shi W,Liu Y

    更新日期:2020-06-01 00:00:00

  • Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

    abstract:BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12791

    authors: Kang J,Chen HJ,Zhang XC,Su J,Zhou Q,Tu HY,Wang Z,Wang BC,Zhong WZ,Yang XN,Chen ZH,Ding Y,Wu X,Wang M,Fu JG,Yang Z,Zhang X,Shao YW,Wu YL,Yang JJ

    更新日期:2018-09-01 00:00:00

  • Experience with the "da Vinci" robotic system for early-stage thymomas: Report of 23 cases.

    abstract:BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12097

    authors: Huang P,Ye B,Yang Y,Tantai JC,Zhao H

    更新日期:2014-07-01 00:00:00

  • Soluble fms-like tyrosine kinase-1-enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration.

    abstract:BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13175

    authors: Hao D,Li Y,Zhao G,Zhang M

    更新日期:2019-10-01 00:00:00

  • Micro ribonucleic acid-93 promotes proliferation and migration of esophageal squamous cell carcinoma by targeting disabled 2.

    abstract:BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12242

    authors: Li C,Ding C,Chen T,Chen J,Xu Z,Lei Z,Xu C,Zhao J

    更新日期:2015-07-01 00:00:00

  • Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer.

    abstract:BACKGROUND:This study investigates the outcome of synchronous stage IV non-small cell lung cancer (NSCLC) patients who received radical thoracic radiotherapy (TRT). METHODS:We retrospectively reviewed the charts of stage IV NSCLC patients treated with TRT between January 2007 and December 2011. Radiotherapy was consid...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12305

    authors: Wang J,Ji Z,Wang X,Liang J,Hui Z,Lv J,Zhou Z,Yin W,Wang L

    更新日期:2016-03-01 00:00:00

  • Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.

    abstract:BACKGROUND:If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK-tyrosine kinase inhibitors (ALK-TKIs) can be an effective treatment. However, the details of drug-induced lung injury (DILI) caused by ALK-TKI, which can be a serious side effect of ALK-TKIs, remains unclear. This study ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13416

    authors: Koshikawa K,Terada J,Abe M,Iwasawa S,Sakayori M,Yoshioka K,Hirasawa Y,Kasai H,Kawasaki Y,Tsushima K,Tatsumi K

    更新日期:2020-06-01 00:00:00

  • Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.

    abstract:BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13526

    authors: Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

    更新日期:2020-08-01 00:00:00

  • The 12th National Lung Cancer Academic Conference in China.

    abstract:BACKGROUND:  The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS:  The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00125.x

    authors: Liu Y,Chen G,Qiu X,Chen J,Zhou Q

    更新日期:2012-08-01 00:00:00

  • Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug-eluting beads in patients with stage II-IV lung cancer: A prospective cohort study.

    abstract:BACKGROUND:CalliSpheres are drug-eluting beads used for tumor artery embolization, with clinical benefits in a number of cancer types. The aim of the study was to examine the clinical benefits and complications of patients with stage II-IV lung cancer treated with CalliSpheres drug-eluting beads for embolization versus...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13522

    authors: Shang B,Li J,Wang X,Li D,Liang B,Wang Y,Han X,Dou W,Chen G,Shang J,Jiang S

    更新日期:2020-08-01 00:00:00

  • Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.

    abstract:BACKGROUND:The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12818

    authors: Cui J,Zhang Y,Su D,Li T,Li Y

    更新日期:2018-09-01 00:00:00

  • A case of huge esophageal carcinosarcoma.

    abstract::Carcinosarcoma of the esophagus is a rare malignant neoplasm with both epithelial and mesenchymal (sarcomatous) components. We describe a case of a 72-year-old man with a huge esophageal tumor which could often have been considered inoperable. However, the patient underwent a curative resection and had a good prognosi...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2011.00069.x

    authors: Hu M,Zhi XY,Sun KL

    更新日期:2011-11-01 00:00:00

  • Influence of different image-guided tracking methods upon the local efficacy of CyberKnife treatment in lung tumors.

    abstract:BACKGROUND:The aim of this study was to explore the influence of image-guided tumor localization modality (Synchrony tracking vs. Xsight spine-based localization) on the local efficacy of CyberKnife treatment in lung cancer and lung metastases. METHODS:Retrospective analysis of 64 patients with pulmonary metastases an...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12174

    authors: Guo Y,Zhuang H,Zhao L,Yuan Z,Wang P

    更新日期:2015-05-01 00:00:00

  • Primary inflammatory myofibroblastic tumor of the diaphragm: Report of a case.

    abstract::We report a case of primary inflammatory myofibroblastic tumor of the diaphragm in a 64-year-old man. The patient was hospitalized for a computed tomography (CT)-detected large tissue mass at the left lower lung field. Complete tumor excision followed by pathological investigation was performed. Microscopically, the t...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2012.00155.x

    authors: Fu J,Wu Q,Zhang Y,Zhang X,Wang Z

    更新日期:2013-11-01 00:00:00

  • CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.

    abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12617

    authors: Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

    更新日期:2018-05-01 00:00:00

  • Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).

    abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS:The MeSO-CLICaP registry identified 302 patients with advanced MPM diagnose...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12967

    authors: Rojas L,Cardona AF,Trejo-Rosales R,Zatarain-Barrón ZL,Ramírez-Tirado LA,Ruiz-Patiño A,Campos Gómez S,Corrales L,Oblitas G,Bacon L,Martín C,de Lima VCC,Freitas HC,Mas L,Vargas C,Carranza H,Otero J,Pérez MA,González L,

    更新日期:2019-03-01 00:00:00

  • Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.

    abstract:BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13226

    authors: Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

    更新日期:2019-12-01 00:00:00

  • Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study.

    abstract:BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00152.x

    authors: Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

    更新日期:2013-05-01 00:00:00

  • Overexpression of micro ribonucleic acid-591 inhibits cell proliferation and invasion of malignant pleural mesothelioma cells.

    abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive cancer refractory to current therapies. Reduced expression of micro ribonucleic acid (miR)-591 in a range of cancer types has suggested it is a potent tumor suppressor, and overexpression has been shown to inhibit tumor cell growth. The role of miR-591 in...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12336

    authors: Cheng S,Xu Y,Shi Z,Lin Y,Hoang CD,Zhang X

    更新日期:2016-04-26 00:00:00

  • Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

    abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12275

    authors: Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

    更新日期:2016-01-01 00:00:00

  • Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.

    abstract:BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12877

    authors: Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

    更新日期:2018-11-01 00:00:00

  • Cloning short DNA into plasmids by one-step PCR.

    abstract:BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13660

    authors: Tao CC,Yang Y,Li F,Qiao L,Wu Y,Sun XD,Zhang YY,Li CL

    更新日期:2020-11-01 00:00:00

  • Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.

    abstract::SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13215

    authors: Takada K,Sugita S,Murase K,Kikuchi T,Oomori G,Ito R,Hayasaka N,Miyanishi K,Iyama S,Ikeda H,Kobune M,Emori M,Kato J,Hasegawa T

    更新日期:2019-12-01 00:00:00

  • Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO).

    abstract:BACKGROUND:Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outc...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12150

    authors: Unal OU,Oztop I,Yasar N,Urakci Z,Ozatli T,Bozkurt O,Sevinc A,Gunaydin Y,Yapar Taskoylu B,Arpaci E,Ulas A,Kodaz H,Tonyali O,Avci N,Aksoy A,Yilmaz AU

    更新日期:2015-01-01 00:00:00

  • Impact of target area selection in 125 Iodine seed brachytherapy on locoregional recurrence in patients with non-small cell lung cancer.

    abstract:BACKGROUND:Computed tomography (CT)-guided percutaneous implantation of 125 Iodine radioactive seeds requires the precise arrangement of seeds by tumor shape. We tested whether selecting target areas, including subclinical areas around tumors, can influence locoregional recurrence in patients with non-small cell lung c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12415

    authors: Yan WL,Lv JS,Guan ZY,Wang LY,Yang JK,Liang JX

    更新日期:2017-05-01 00:00:00